D000964Chemicals & DrugsD27.505.519.186.144D27.505.954.248.144D27.888.569.042.03037812980.615833Antimetabolites, AntineoplasticFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonExperimental TherapeuticsLeukemiaMD AndersonHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorWILLIAM KPLUNKETT JRWILLIAM K PLUNKETT JR8426PLUNKETT JR, WILLIAM KProfessorELIAS JOSEPHJABBOURELIAS JOSEPH JABBOUR9124JABBOUR, ELIAS JOSEPHAssociate ProfessorFARHADRAVANDI-KASHANIFARHAD RAVANDI-KASHANI8745RAVANDI-KASHANI, FARHADProfessorGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessor74Professor14Associate Professor8.67430.00534203378research area of0.8361420.0247467592subject area for32377978Ajani JA, Javle M, Eng C, Fogelman D, Smith J, Anderson B, Zhang C, Iizuka KInvestigational new drugsPhase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 12; 38(6):1763-1773.Invest New Drugs2020-05-06T00:00:002020Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors.32608575Mangum R, Bernhardt MB, Cheng WS, Schafer ES, Berg SL, Foster JHPediatric blood & cancerDo intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage. Pediatr Blood Cancer. 2020 09; 67(9):e28334.Pediatr Blood Cancer2020-07-01T00:00:002020Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage.33705966Garcia JS, Swords RT, Roboz GJ, Jacoby MA, Garcia-Manero G, Hong WJ, Yang X, Zhou Y, Platzbecker U, Steensma DP, Wolff JE, Fenaux PLeukemia researchA systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leuk Res. 2021 05; 104:106555.Leuk Res2021-03-02T00:00:002021A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.33678567Jackisch C, Barcenas CH, Bartsch R, Palma JD, Gl?ck S, Harbeck N, Macedo G, O'Shaughnessy J, Pistilli B, Ruiz-Borrego M, Rugo HSClinical breast cancerOptimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. Clin Breast Cancer. 2021 10; 21(5):e575-e583.Clin Breast Cancer2021-02-06T00:00:002021Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.34454540Ravandi F, Roboz GJ, Wei AH, D?hner H, Pocock C, Selleslag D, Montesinos P, Sayar H, Musso M, Figuera-Alvarez A, Safah H, Tse W, Sohn SK, Hiwase D, Chevassut T, Pierdomenico F, La Torre I, Skikne B, Bailey R, Zhong J, Beach CL, Dombret HJournal of hematology & oncologyManagement of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. J Hematol Oncol. 2021 08 28; 14(1):133.J Hematol Oncol2021-08-28T00:00:002021Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor